Commentary|Podcasts|September 28, 2023

Venture Creation Firm Reveals Strategies for Launching New Companies & Forming Collaborations

Author(s)Meg Rivers

An expert from Flagship Pioneering, the venture creation firm behind Moderna and other life science firms, shares the process of founding a company, how they decide whether to partner with companies, the importance of collaboration and how they approach it, and where science is booming in pharma right now.

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about:

  • The process of founding a company
  • What factors they consider when deciding whether to partner with a pharmaceutical company (like their partnership with Novo Nordisk) or a foundation (like their partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another
  • Where science is booming in pharma right now
  • Deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space
  • Signs that a company will achieve commercial success from early on

About the speaker

Paul Biondi is an executive partner at Flagship Pioneering and president of Pioneering Medicines. In his role at Flagship, Biondi works with growth company CEOs and their teams to achieve the best attainable value for each company and serves on the boards of selected Flagship companies, including Seres Therapeutics and Valo Health. Biondi joined Flagship following many years at Bristol-Myers Squibb where he held senior leadership roles in both business development and research and development.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.